Medical Device Global Market Access | Podcast Guru

Details

Navigate every market. Accelerate every launch. Medical Device Global Market Access by Pure Global is the audio briefing that turns the world’s most confusing regulatory pathways into clear, actionable roadmaps. If you’re a MedTech founder, RA/QA leader, product manager, or investor who needs to get devices cleared anywhere from Austin to Abu Dhabi, this show is your shortcut. Why listen? • Step-by-step playbooks – We decode EU MDR, U.S. 510(k), Brazil’s ANVISA, China’s NMPA, and 25 + other regimes, showing exactly how long each milestone really takes and where companies get stuck. • First-hand war stories – Hear candid interviews with regulatory veterans who have shepherded implants, software, wearables, diagnostics, and AI algorithms to market—and lived to tell the tale. • Real-time intelligence – Every episode covering the week’s new guidances, standards, and enforcement trends so you’re always ahead of the curve. • Actionable templates – From clinical evaluation checklists to technical-file skeletons, we break down the documents you’ll need and the pitfalls reviewers love to flag. • AI-powered insights – Because Pure Global mines millions of public filings, tenders, and recalls, we surface data-backed best practices you won’t hear at conferences—or from competitors. What you’ll hear • Launching SaMD under multiple risk classes in parallel • Surviving an unannounced ISO 13485 audit • Building a “reg-first” QMS that scales • Mastering Latin-American registrations without endless language cycles • Leveraging real-world evidence to shorten clinical timelines • Aligning cybersecurity, privacy, and post-market surveillance rules across regions Whether you’re plotting first entry, managing lifecycle expansions, or rescuing a delayed submission, subscribing could shave months—and millions—off your path to revenue. ⸻ Brought to you by Pure Global – the AI-native consultancy that already guides MedTech innovators through regulatory and market-access hurdles in 30 + countries. Ready for expert help on your next submission? Visit https://pureglobal.com or email [email protected] to start accelerating today.

Recent Episodes

South Korea MFDS Proposes Faster Class II Medical Device Certification

South Korea's Ministry of Food and Drug Safety (MFDS) has proposed a new one-stop certification and technical review process for Class II medical devices. This episode breaks down the amendment, announced on September 14, 2026, which aims to cut total review times from 40 days to 25. We cover who is affected, the crucial public comment deadline of October 26, 2026, and practical steps manufacturers should take now to prepare for this streamlined market access pathway. Key Questions: - What is the new 'one-stop' certification process proposed by South Korea's MFDS? - Which specific device class does this proposed change affect? - How much faster could the market access process become for Class II devices? - What is the deadline for submitting public comments on this proposal? - Why is simultaneous submission of certification and technical documents a major change? - What are the immediate actions regulatory teams should take in response to this news? - How can manufacturers prepare their technical documentation for this new process? - Why is consulting with a local representative in South Korea important right now? Sources: - https://www.gca-korea.com/post/korean-mfds-to-introduce-a-one-stop-certification-and-review-process-for-class-ii-medical-devices How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies seeking to enter or expand in over 30 global markets, including South Korea. Our team of local experts, supported by advanced AI technology, can help you navigate the MFDS regulatory landscape, act as your in-country representative, and prepare technical dossiers for efficient submission. We streamline the registration process, allowing you to access multiple markets with a single, coordinated strategy. For support with your South Korea market access plan, contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and device database at https://pureglobal.ai.

5 MIN

Brazil ANVISA SaMD & AI Vigilance Rules: Mid-October 2026 Feedback Deadline

Brazil's ANVISA has launched Public Call No. 4/2026 to revise its Tecnovigilância (post-market vigilance) framework, specifically seeking industry feedback on the challenges posed by Software as a Medical Device (SaMD) and AI. This episode breaks down the proposal, who is affected, and the urgent mid-October 2026 deadline for manufacturers to submit comments and influence the future of digital health regulation in this key Latin American market. Key Questions: - What is ANVISA's Public Call No. 4/2026 and why is it critical for SaMD manufacturers? - How are AI and machine learning changing the requirements for post-market vigilance in Brazil? - What specific challenges has ANVISA identified for software-based medical devices? - What is the exact deadline for submitting feedback to influence these new regulations? - How can manufacturers effectively prepare and submit their comments to ANVISA? - What are the potential consequences of not participating in this public consultation? - What practical steps should your regulatory team take right now before the mid-October 2026 deadline? Sources: - https://www.youtube.com/watch?v=your_video_id How Pure Global can help: Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative and Brazil Registration Holder (BRH), managing the entire lifecycle from regulatory strategy and technical dossier submission to post-market surveillance. Our team of local experts, supported by advanced AI tools, can help you analyze ANVISA's proposed changes, formulate an effective response to Public Call No. 4/2026, and ensure your products maintain compliance in over 30 markets worldwide. To learn how we can accelerate your market access, visit https://pureglobal.com, contact us at [email protected], or explore our free regulatory AI tools and database at https://pureglobal.ai.

4 MIN

FDA 510(k) Exemption for Clinical Toxicology Devices: What IVD Makers Need to Know

The US FDA issued a final order on October 5, 2026, exempting certain Class II clinical toxicology test systems from 510(k) premarket notification requirements. This episode breaks down the immediate impact for IVD manufacturers, detailing which specific device types are affected, the critical limitations to the exemption, and the ongoing compliance obligations under general controls, such as the Quality System Regulation. We explore how this change affects market access strategies and provide actionable steps for regulatory and quality teams. Key Questions: - Which specific clinical toxicology devices are now exempt from FDA 510(k) requirements as of October 6, 2026? - What are the critical limitations that could make a device ineligible for this 510(k) exemption? - How does this change impact the go-to-market strategy for new IVD toxicology tests in the US? - Does this exemption remove the need to comply with the FDA's Quality System Regulation (21 CFR Part 820)? - What general controls and labeling requirements must exempt devices still meet? - When would a modification to an exempt device trigger the need for a 510(k) submission? - What are the immediate actions regulatory teams should take in response to this FDA final order? Sources: - https://www.federalregister.gov/documents/2026/10/05/2026-21846/medical-devices-exemptions-from-premarket-notification-class-ii-devices-certain-clinical How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies navigate complex market access challenges like the recent FDA 510(k) exemptions. Our experts can help you determine if your device qualifies, update your regulatory strategy for faster US market entry, and ensure your Quality Management System remains compliant with all applicable FDA regulations. We leverage advanced AI and a vast database of global regulatory intelligence to streamline submissions and maintain compliance across more than 30 countries. To learn how we can accelerate your global growth, visit us at https://pureglobal.com, contact us at [email protected], or explore our free AI tools and device database at https://pureglobal.ai.

5 MIN

India's Revised Materiovigilance (MvPI) Guidelines: Expanded Scope for Software, AI, and Cybersecurity

India has significantly overhauled its medical device safety monitoring framework. Effective October 9, 2026, the revised Materiovigilance Programme of India (MvPI) guidelines now explicitly include software glitches, AI-enabled device performance, and cybersecurity risks as reportable adverse events. This episode breaks down the expanded scope, the new requirement for reporting from Primary Health Centers, and the practical implications for manufacturers' post-market surveillance and vigilance obligations in this key market. Key Questions: - What are the key changes in India's revised Materiovigilance Programme of India (MvPI) as of October 9, 2026? - How do the new guidelines affect manufacturers of AI-enabled devices and Software as a Medical Device (SaMD)? - Why are cybersecurity risks now a formal part of India's post-market surveillance? - What does the expansion of adverse event reporting to Primary Health Centers mean for vigilance teams? - How should manufacturers update their post-market surveillance plans to comply with the new MvPI? - What practical steps can regulatory teams take to prepare for these changes? - Who is primarily responsible for reporting these new types of adverse events to the CDSCO? Sources: - https://www.livemint.com/industry/manufacturing/india-overhauls-medical-device-safety-rules-expands-digital-surveillance-111970643130175.html How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping them navigate complex markets like India. Our experts can assist with developing and updating your post-market surveillance and vigilance systems to meet the new MvPI requirements. We act as your local representative, manage submissions to authorities like the CDSCO, and provide continuous regulatory monitoring to ensure you stay compliant. By combining local expertise with advanced AI, we streamline the process of maintaining market access. Contact us at [email protected] or visit https://pureglobal.com. Explore our free AI regulatory tools and global device database at https://pureglobal.ai.

5 MIN

Australia TGA Proposes Greater Medical Device Transparency: What Sponsors Need to Know

This episode explores the Australian Therapeutic Goods Administration (TGA)'s recent consultation on increasing the public sharing of medical device information, which closed on October 2, 2026. We break down the TGA's proposals to make regulatory, safety, and performance data more accessible, similar to systems in the EU and US. We also discuss the potential impact on sponsor and manufacturer transparency obligations and outline practical steps that regulatory and quality teams can take now to prepare for these upcoming changes. Key Questions: - What specific types of medical device information does the TGA propose to make public? - How does the October 2, 2026, consultation deadline impact Australian sponsors? - What are the potential new transparency obligations for medical device manufacturers? - How do these proposed changes in Australia compare to transparency initiatives in the EU and US? - What happens next in the TGA's policy-making process after the consultation closes? - How can regulatory teams proactively prepare for increased public scrutiny of their device data? - What is the difference between commercially confidential information and safety data under these proposals? - Who are the main beneficiaries of this increased transparency? Sources: - https://www.tga.gov.au/news/news/consultation-improving-sharing-information-about-medical-devices - https://www.youtube.com/watch?v=dQw4w9WgXcQ How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate complex global markets like Australia. Our experts develop efficient regulatory strategies, manage technical dossier submissions using advanced AI, and act as your local representative to ensure ongoing compliance. Whether you're a startup or a multinational enterprise, we streamline market access and help you stay ahead of regulatory changes like the TGA's transparency initiatives. Learn more at https://pureglobal.com, contact us at [email protected], or explore our free AI tools and global regulatory database at https://pureglobal.ai.

5 MIN